Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 33
Filtrar
Mais filtros

País/Região como assunto
Intervalo de ano de publicação
1.
Osteoarthritis Cartilage ; 31(2): 167-176, 2023 02.
Artigo em Inglês | MEDLINE | ID: mdl-36179981

RESUMO

OBJECTIVE: To review articles reporting on the development of soluble biomarkers in osteoarthritis (OA) over the past year. DESIGN: Two literature searches were conducted using the PubMed database for articles published between April 1, 2021 and March 31, 2022. Two searches were done, one on soluble biomarkers and another on circulating non-coding RNAs in OA. Additional articles were hand-picked to highlight emerging biomarker trends in OA. RESULTS: Of 348 publications retrieved, we included 20 articles with 3 that were hand-picked for the narrative synthesis. We review recent data on soluble biomarkers and circulating non-coding microRNAs in OA using the BIPED classification system. We highlight studies using proteomics to show that cartilage acidic protein 1 (CRTAC1) is a promising biomarker, helping diagnose and estimate severity in hand, hip, and knee OA. Subtle changes in the structure of glycosaminoglycans from the extracellular cartilage matrix were shown to discriminate OA from non-OA cartilage. C-reactive protein metabolite (CRPM) and collagen metabolites may help discriminate subsets of OA patients as well as disease progression. Additionally, physical activity may impact determination of biomarkers. We also report on circulating microRNAs, lncRNAs, and circRNAs in OA and their predictive accuracy in diagnosis and prognosis. CONCLUSIONS: Biomarkers for routine use are still an unmet need in the OA clinical scenario. Emerging data and novel classes of biomarkers (i.e., non-coding RNAs) show promise. Although still requiring validation in multiple independent cohorts, the past year brought advances towards a ready-to-use, reproducible, cost-effective biomarker, namely CRTAC1, to better manage the OA patient.


Assuntos
MicroRNAs , Osteoartrite do Joelho , Humanos , Biomarcadores/metabolismo , Prognóstico , Osteoartrite do Joelho/metabolismo , Cartilagem/metabolismo , MicroRNAs/metabolismo , Proteínas de Ligação ao Cálcio/metabolismo
2.
Osteoarthritis Cartilage ; 22(11): 1878-85, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-25086402

RESUMO

OBJECTIVE: To evaluate pain behavior and structural damage in mice subjected to either meniscal transection or removal. METHODS: Mice (10/group) were subjected to transection of the medial collateral and anterior cruciate ligaments (ACLT/MCLT) followed by either transection (meniscotomy) or removal (meniscectomy) of the medial meniscus. A control group was subjected only to transection of the ligaments. Pain was assessed using the electronic pressure-meter paw test. Cell influx, measured in joint exudates, and joint histopathology were assessed after 49 days. Four other groups subjected to meniscotomy received indomethacin, the inducible nitric oxide synthase (iNOS) inhibitor 1400W, morphine or the vehicles. RESULTS: Both meniscotomy and meniscectomy groups displayed persistent and significant increase in pain behavior as compared to controls, being significantly more severe in the former. Cell influx was more intense in the meniscotomy as compared to the meniscectomy group. Structural damage at the tibia, but not at the femur, was also more severe in the meniscotomy group. Indomethacin and 1400W partially but significantly reduced pain whereas morphine abrogated pain behavior in meniscotomized mice. CONCLUSION: Meniscal transection rather than resection promotes more severe pain and structural damage in mice. Administration of opioids, cyclooxygenase and nitric oxide (NO) synthase inhibitors provide analgesia in this model. Careful description of the structures damaged is crucial when reporting experimental osteoarthritis (OA).


Assuntos
Artralgia/cirurgia , Cartilagem Articular/patologia , Meniscos Tibiais/patologia , Procedimentos Ortopédicos/métodos , Osteoartrite do Joelho/cirurgia , Animais , Artralgia/etiologia , Cartilagem Articular/cirurgia , Modelos Animais de Doenças , Masculino , Meniscos Tibiais/cirurgia , Camundongos , Osteoartrite do Joelho/complicações , Osteoartrite do Joelho/patologia , Medição da Dor
3.
Mycopathologia ; 176(1-2): 1-10, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23765323

RESUMO

Paracoccidioidomycosis (PCM) is a chronic granulomatous disease caused by the thermally dimorphic fungus Paracoccidioides brasiliensis. T helper 1 (Th1)-mediated immunity is primarily responsible for acquired resistance during P. brasiliensis infection. On the contrary, the susceptibility is associated with occurrence of type-2 immunity (Th2), which is characterized by IL-4 release, B cell activation, and production of antibodies. Although antibodies are frequently associated with severe PCM, it is not clear whether they contribute to susceptibility or merely constitute a marker of infection stage. Here, we assessed the function of B cells during experimental P. brasiliensis infection in mice, and our results showed that B cell-knockout (B(KO)) mice are more susceptible than their wild-type littermate controls (C57BL/6, WT). The B(KO) mice showed higher mortality rate, increased number of colony-forming units in the lungs, and larger granulomas than WT mice. In the absence of B cells, we observed high levels of IL-10, whereas IFN-γ, TNF-α, and IL-4 levels were similar between both groups. Finally, we showed that transference of WT immune serum to B(KO) mice resulted in diminished infiltration of inflammatory cells and better organization of the pulmonary granulomas. Taken together, these data suggest that B cells are effectively involved in the control of P. brasiliensis growth and organization of the granulomatous lesions observed during the experimental PCM.


Assuntos
Linfócitos B/imunologia , Suscetibilidade a Doenças , Paracoccidioides/imunologia , Paracoccidioidomicose/imunologia , Animais , Contagem de Colônia Microbiana , Citocinas/metabolismo , Modelos Animais de Doenças , Granuloma/patologia , Pulmão/microbiologia , Pulmão/patologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Análise de Sobrevida
4.
Lupus ; 21(4): 445-8, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21997967

RESUMO

Protein-losing enteropathy is a rare manifestation of systemic lupus erythematosus. We report the case of an 18-year-old woman that presented initially with diarrhoea and anasarca. During evaluation, there was low serum albumin of 1.6 g/dl (3.5-5.2 g/dl) and a positive antinuclear antibody test (1:2560). Anti-Sm antibodies (ELISA) were positive in addition to low serum C3 of 35 mg/dl. A scintigraphy using 99mTc-labelled albumin was positive for abdominal protein loss. A diagnosis of systemic lupus erythematosus related protein-losing enteropathy was made. She was started on prednisolone 40 mg/day without amelioration; a month later, azathioprine (100 mg/day) was added, leading to normalization of serum albumin and resolution of symptoms within 4 months. After 1.5 years, the patient developed a 2.9 g 24-h proteinuria while still in remission of the protein-losing enteropathy, receiving 5 mg prednisone and 100 mg azathioprine daily.


Assuntos
Lúpus Eritematoso Sistêmico/complicações , Lúpus Eritematoso Sistêmico/diagnóstico , Enteropatias Perdedoras de Proteínas/diagnóstico , Enteropatias Perdedoras de Proteínas/etiologia , Adolescente , Anticorpos Antinucleares/sangue , Azatioprina/uso terapêutico , Biomarcadores/sangue , Complemento C3/análise , Diarreia/etiologia , Quimioterapia Combinada , Edema/etiologia , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Hipoalbuminemia/etiologia , Imunossupressores/uso terapêutico , Lúpus Eritematoso Sistêmico/sangue , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Nefrite Lúpica/etiologia , Prednisolona/uso terapêutico , Prednisona/uso terapêutico , Enteropatias Perdedoras de Proteínas/sangue , Enteropatias Perdedoras de Proteínas/tratamento farmacológico , Proteinúria/etiologia , Albumina Sérica/análise , Fatores de Tempo , Resultado do Tratamento
5.
Clin Exp Rheumatol ; 30(3): 351-7, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22510473

RESUMO

OBJECTIVES: To analyse demographic and clinical variables in patients with disease onset before and after 40, 45 and 50 years in a large series of Brazilian SpA patients. METHODS: A common protocol of investigation was prospectively applied to 1424 SpA patients in 29 centres distributed through the main geographical regions in Brazil. The mean age at disease onset was 28.56 ± 12.34 years, with 259 patients (18.2%) referring disease onset after 40 years, 151 (10.6%) after 45 years and 81 (5.8%) after 50 years. Clinical and demographic variables and disease indices (BASDAI, BASFI, BASRI, MASES, ASQoL) were investigated. Ankylosing spondylitis was the most frequent disease (66.3%), followed by psoriatic arthritis (18%), undifferentiated SpA (6.7%), reactive arthritis (5.5%), and enteropathic arthritis (3.5%). RESULTS: Comparing the groups according to age of disease onset, those patients with later onset presented statistical association with female gender, peripheral arthritis, dactylitis, nail involvement and psoriasis, as well as negative statistical association with inflammatory low back pain, alternating buttock pain, radiographic sacroiliitis, hip involvement, positive familial history, HLA-B27 and uveitis. BASDAI, BASFI and quality of life, as well as physicians and patient's global assessment, were similar in all the groups. Radiographic indices showed worse results in the younger age groups. CONCLUSIONS: There are two different clinical patterns in SpA defined by age at disease onset: one with predominance of axial symptoms in the group with disease onset ≤ 40 years and another favouring the peripheral manifestations in those with later disease onset.


Assuntos
Índice de Gravidade de Doença , Espondilartrite/epidemiologia , Espondilartrite/fisiopatologia , Espondilite Anquilosante/epidemiologia , Espondilite Anquilosante/fisiopatologia , Adolescente , Adulto , Distribuição por Idade , Idade de Início , Idoso , Brasil/epidemiologia , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Adulto Jovem
6.
Lupus ; 19(5): 583-90, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20156929

RESUMO

The involvement of the peripheral nervous system in diverse autoimmune diseases is well established. However, no appropriately designed studies have been performed in primary antiphospholipid syndrome (PAPS)-related peripheral neuropathy. We aimed to investigate the occurrence of peripheral neuropathy in patients diagnosed with PAPS. Twenty-six consecutive patients with PAPS (Sapporo criteria) and 20 age- and gender-matched healthy controls were enrolled at two referral centers. Exclusion criteria were secondary causes of peripheral neuropathy. A complete clinical neurologic exam followed by nerve conduction studies (NCS) was performed. Paresthesias were reported in eight patients (31%). Objective mild distal weakness and abnormal symmetric deep tendon reflexes were observed in three patients (11.5%). With regard to the electrophysiologic evidence of peripheral neuropathy, nine patients (35.0%) had alterations: four (15.5%) had pure sensory or sensorimotor distal axonal neuropathy (in two of them a carpal tunnel syndrome was also present) and one (4%) had sensorimotor demyelinating and axonal neuropathy involving upper and lower extremities, while four patients (15.5%) showed isolated carpal tunnel syndrome. Clinical and serologic results were similar in all the patients with PAPS, regardless of the presence of electrophysiologic alterations. In conclusion, peripheral neuropathy is a common asymptomatic abnormality in patients with PAPS. The routine performance of NCS may be considered when evaluating such patients.


Assuntos
Síndrome Antifosfolipídica/complicações , Doenças do Sistema Nervoso Periférico/etiologia , Adulto , Feminino , Humanos , Masculino
7.
Clin Exp Rheumatol ; 28(4): 454-61, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20810033

RESUMO

OBJECTIVES: To investigate whether body mass index (BMI), as a proxy for body fat, influences rheumatoid arthritis (RA) disease activity in a gender-specific manner. METHODS: Consecutive patients with RA were enrolled from 25 countries into the QUEST-RA program between 2005 and 2008. Clinical and demographic data were collected by treating rheumatologists and by patient self-report. Distributions of Disease Activity Scores (DAS28), BMI, age, and disease duration were assessed for each country and for the entire dataset; mean values between genders were compared using Student's t-tests. An association between BMI and DAS28 was investigated using linear regression, adjusting for age, disease duration and country. RESULTS: A total of 5,161 RA patients (4,082 women and 1,079 men) were included in the analyses. Overall, women were younger, had longer disease duration, and higher DAS28 scores than men, but BMI was similar between genders. The mean DAS28 scores increased with increasing BMI from normal to overweight and obese, among women, whereas the opposite trend was observed among men. Regression results showed BMI (continuous or categorical) to be associated with DAS28. Compared to the normal BMI range, being obese was associated with a larger difference in mean DAS28 (0.23, 95% CI: 0.11, 0.34) than being overweight (0.12, 95% CI: 0.03, 0.21); being underweight was not associated with disease activity. These associations were more pronounced among women, and were not explained by any single component of the DAS28. CONCLUSIONS: BMI appears to be associated with RA disease activity in women, but not in men.


Assuntos
Artrite Reumatoide/fisiopatologia , Índice de Massa Corporal , Índice de Gravidade de Doença , Caracteres Sexuais , Adulto , Idoso , Avaliação da Deficiência , Feminino , Humanos , Modelos Lineares , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Autorrevelação
8.
Vis Neurosci ; 25(3): 307-15, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18598402

RESUMO

The turtle retina has been extensively used for the study of chromatic processing mechanisms. Color opponency has been previously investigated with trichromatic paradigms, but behavioral studies show that the turtle has an ultraviolet (UV) channel and a tetrachromatic visual system. Our laboratory has been working in the characterization of neuronal responses in the retina of vertebrates using stimuli in the UV-visible range of the electromagnetic spectrum. In the present investigation, we recorded color-opponent responses from turtle amacrine and ganglion cells to UV and visible stimuli and extended our previous results that UV color-opponency is present at the level of the inner nuclear layer. We recorded from 181 neurons, 36 of which were spectrally opponent. Among these, there were 10 amacrine (5%), and 26 ganglion cells (15%). Morphological identification of color-opponent neurons was possible for two ganglion cell classes (G17 and G22) and two amacrine cell classes (A22 and A23b). There was a variety of cell response types and a potential for complex processing of chromatic stimuli, with intensity- and wavelength-dependent response components. Ten types of color opponency were found in ganglion cells and by adding previous results from our laboratory, 12 types of opponent responses have been found. The majority of the ganglion cells were R+UVBG- and RG+UVB-color-opponents but there were other less frequent types of chromatic opponency. This study confirms the participation of a UV channel in the processing of color opponency in the turtle inner retina and shows that the turtle visual system has the retinal mechanisms to allow many possible chromatic combinations.


Assuntos
Percepção de Cores/fisiologia , Células Ganglionares da Retina/citologia , Células Ganglionares da Retina/fisiologia , Vias Visuais/fisiologia , Animais , Gânglios dos Invertebrados/fisiologia , Microscopia Confocal , Microscopia de Fluorescência , Neurônios/fisiologia , Células Fotorreceptoras Retinianas Cones/fisiologia , Tartarugas , Raios Ultravioleta
9.
Br J Pharmacol ; 151(8): 1254-61, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17592506

RESUMO

BACKGROUND AND PURPOSE: Matrix metalloproteinases (MMPs) have been implicated in joint tissue destruction in arthritis. However, MMPs have not been assigned a role in joint pain. We investigated the ability of BaP1, a metalloproteinase from Bothrops asper snake venom, with structural homology to MMPs, to induce joint hypernociception. EXPERIMENTAL APPROACH: Animals received intra-articular (i.art.) BaP1. Hypernociception was assessed using the rat-knee joint articular incapacitation test. Cell influx, prostaglandin E(2) (PGE(2)), and TNF-alpha levels were assessed in joint exudates following BaP1 injection. KEY RESULTS: BaP1 (5 microg per joint) provoked hypernociception between 1 and 6 h after i.art. injection. Cell influx, mostly neutrophils, was maximal 3 h after BaP1 i.art. injection. BaP1 also led to increase in PGE(2) and TNF-alpha levels in the joint exudates. Pretreatment with either indomethacin (4 mg.kg(-1) i.p.) or with an anti-TNF-alpha antiserum (i.art.) significantly inhibited both BaP1-induced joint hypernociception and cell influx. In isolated rat peritoneal macrophages, BaP1 increased cyclooxygenase (COX)-2 expression, while not altering that of COX-1. CONCLUSIONS AND IMPLICATIONS: This is the first demonstration that a metalloproteinase promotes joint hypernociception. This effect involves local release of PGE(2) and TNF-alpha. BaP1-induced increase in PGE(2) is associated to increased COX-2 expression in macrophages. Blocking PGE(2) or TNF-alpha inhibits BaP1-induced hypernociception. In addition to unravelling a hitherto unknown mechanism whereby TNF blockade provides analgesia in arthritis, the data show, for the first time that MMPs are involved in inflammatory joint hypernociception and induce COX-2 expression.


Assuntos
Artrite Experimental/fisiopatologia , Venenos de Crotalídeos/toxicidade , Metaloendopeptidases/toxicidade , Dor/induzido quimicamente , Animais , Anti-Inflamatórios não Esteroides/uso terapêutico , Bothrops , Ciclo-Oxigenase 1/efeitos dos fármacos , Ciclo-Oxigenase 1/metabolismo , Ciclo-Oxigenase 2/efeitos dos fármacos , Ciclo-Oxigenase 2/metabolismo , Dinoprostona/metabolismo , Exsudatos e Transudatos/metabolismo , Soros Imunes , Indometacina/uso terapêutico , Injeções Intra-Articulares , Cápsula Articular/efeitos dos fármacos , Cápsula Articular/fisiopatologia , Articulação do Joelho/efeitos dos fármacos , Articulação do Joelho/fisiopatologia , Macrófagos Peritoneais/efeitos dos fármacos , Macrófagos Peritoneais/metabolismo , Masculino , Neutrófilos , Ratos , Ratos Wistar , Fator de Necrose Tumoral alfa/efeitos dos fármacos , Fator de Necrose Tumoral alfa/metabolismo
10.
Braz J Med Biol Res ; 39(5): 671-5, 2006 May.
Artigo em Inglês | MEDLINE | ID: mdl-16648905

RESUMO

Pemphigus is an inflammatory autoimmune disorder of the skin. Nitric oxide (NO) is an inflammatory mediator linked to a variety of physiological and pathophysiological phenomena that include skin tumors, psoriasis, urticaria, and atopic dermatitis. Inflammatory cells present in pemphigus lesions are important sources of NO production. We investigated whether NO is involved in pemphigus. A prospective cohort study was conducted at the Dermatology Service of the Hospital Universitário Walter Cantídio of the Federal University of Ceará. All patients seen at the outpatient clinic between August 2000 and July 2001, with a clinically and histologically confirmed diagnosis of pemphigus were included. The median age was 42.5 years (range: 12-69 years) with a male to female ratio of 3:2. Total serum nitrite levels, used as a marker for NO production, were determined by the Griess reaction. Skin biopsies from pemphigus and breast surgery (control) patients were used for the detection of the inducible NO synthase (iNOS) by immunohistochemistry. Twenty-two (22) patients with pemphigus and eight (8) controls who did not differ in demographic characteristics were included. Total serum nitrite levels were significantly higher (>7 micromol/L) in pemphigus patients compared to controls (<6 micromol/L), regardless of the severity of the clinical activity of pemphigus (P < 0.0001). All pemphigus biopsies presented increased immunostaining for iNOS that was not detected in normal skin samples. These data are the first to demonstrate that pemphigus patients display increased serum NO levels that are associated with increased iNOS expression in the affected skin.


Assuntos
Óxido Nítrico Sintase Tipo II/metabolismo , Óxido Nítrico/metabolismo , Pênfigo/enzimologia , Adolescente , Adulto , Idoso , Biomarcadores/sangue , Estudos de Casos e Controles , Criança , Estudos de Coortes , Etilenodiaminas , Feminino , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Nitratos/sangue , Nitritos/sangue , Pênfigo/etiologia , Estudos Prospectivos , Índice de Gravidade de Doença , Sulfanilamidas
11.
J Periodontol ; 76(6): 956-63, 2005 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15948691

RESUMO

BACKGROUND: Periodontitis is the most frequent cause of tooth loss in adults. Nitric oxide (NO) has been linked to bone resorption mechanisms during inflammation processes. The aim of this study was to investigate the effect of NOS (NO synthase) inhibitors in the alveolar bone loss in an experimental periodontitis disease (EPD) model. METHODS: Wistar rats were subjected to a ligature placement around the second upper left molars and were sacrificed at 11 days. Alveolar bone loss was evaluated by the sum of distances between the cusp tips and the alveolar bone along the axis of each molar root, subtracting from the contralateral side. Histopathological analysis was based on cell influx, alveolar bone, and cementum integrity. Leukogram was performed at 6 hours and 1, 7, and 11 days after the EPD induction. Groups were treated with the NOS inhibitors, aminoguanidine (AG) (2.5 to 10 mg/kg/d), or L-arginine methyl ester (L-NAME, 5 to 20 mg/kg/d) intraperitoneally (i.p.), 1 hour before the EPD induction and daily for 11 days. Controls received only saline (EPD group). As controls for L-NAME specificity, groups were co-treated with either L-arginine (150 to 600 mg/kg/d) or D-arginine (600 mg/kg/d) and L-NAME (20 mg/kg/d). Different groups were used for morphometric and histopathological analysis. RESULTS: Both L-NAME and AG significantly and dose-dependently inhibited the alveolar bone loss as compared to EPD group. L-NAME (20 mg/kg/d) reduced the alveolar bone loss by 50%, whereas AG (5 mg/kg/d) reduced it by 47% compared to EPD. This result was coupled to a significant reduction of cell influx to the periodontium, as well as to the preservation of alveolar bone and cementum, seen at histopathology, for both compounds. The co-administration of L-arginine, but not of D-arginine reversed L-NAME effects. CONCLUSION: These data provide evidence that NOS inhibitors prevent inflammatory bone resorption in experimental periodontitis.


Assuntos
Perda do Osso Alveolar/prevenção & controle , Inibidores Enzimáticos/farmacologia , Óxido Nítrico Sintase/antagonistas & inibidores , Periodontite/complicações , Perda do Osso Alveolar/enzimologia , Animais , Guanidinas/farmacologia , Ligadura , NG-Nitroarginina Metil Éster/farmacologia , Periodontite/enzimologia , Ratos , Ratos Wistar
12.
Br J Pharmacol ; 136(7): 985-94, 2002 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12145098

RESUMO

1: We have examined the relationship between neutrophil accumulation, NO(*) production and nitrated protein levels in zymosan-mediated inflammation in rat skin in vivo. 2: Rats were anaesthetized and cutaneous inflammation was induced by zymosan (injected intradermally, i.d.). Experiments were carried out up to 48 h, in recovery procedures as appropriate. Assays for neutrophil accumulation (measurement of myeloperoxidase), nitric oxide (assessment of NO(2)(-)/NO(3)(-)) and nitrated proteins (detected by ELISA and Western blot) were performed in skin extracts. 3: The results demonstrate a close temporal relationship between these parameters. Samples were assayed at 1, 4, 8, 24 and 48 h after i.d. injection of zymosan. The highest levels measured of each parameter (P<0.001 compared with vehicle) were found at 4-8 h, with a reduction towards basal levels by 24 h. 4: Selective depletion of circulating neutrophils with anti-neutrophil antibody abolished neutrophil accumulation and protein nitration. In addition substantially decreased NO levels were found. 5: A selective inducible nitric oxide synthase (iNOS) inhibitor, N-3-aminomethyl-benzyl-acetamidine-dihydrochloride (1400W) also significantly reduced neutrophil levels and NO production and substantially inhibited protein nitration. 6: We conclude that the neutrophil leukocyte plays an essential role in the formation of iNOS-derived NO and nitrated proteins in inflammation, in a time-dependent and reversible manner. The NO-derived iNOS also has a role in stimulating further neutrophil accumulation into skin. This suggests a close mechanistic coupling between neutrophils, NO production and protein nitration.


Assuntos
Neutrófilos/metabolismo , Óxido Nítrico Sintase/biossíntese , Óxido Nítrico/biossíntese , Proteínas/metabolismo , Pele/metabolismo , Análise de Variância , Animais , Western Blotting , Toxidermias/metabolismo , Toxidermias/patologia , Indução Enzimática , Ensaio de Imunoadsorção Enzimática , Imuno-Histoquímica , Masculino , Peso Molecular , Neutrófilos/fisiologia , Óxido Nítrico Sintase Tipo II , Proteínas/química , Ratos , Ratos Wistar , Pele/enzimologia , Pele/patologia , Zimosan
13.
Artigo em Inglês | MEDLINE | ID: mdl-11334557

RESUMO

Prostaglandins have complex actions on bone metabolism that depend on interactions with different types and subtypes of receptors. Our objective was to characterize the prostaglandins receptors present in primary cultures of human osteoblasts. RT-PCR analysis revealed the presence of DP, EP(4), IP, FP and TP receptor mRNA in primary cultures of human osteoblasts. FP receptor mRNA was detected only after 3 weeks of confluency, all the others were detected at every culture time tested. To verify the functionality of these receptors we challenged the cells with the prostanoids and synthetic analogues and determined the intracellular levels of cAMP. All receptors found by RT-PCR were coupled to second messengers except for the DP subtype. These results clearly show the presence of functional EP(4), IP, FP and TP receptors in human osteoblasts in culture.


Assuntos
Osteoblastos/metabolismo , Receptores de Prostaglandina/biossíntese , Receptores de Prostaglandina/química , Cálcio/metabolismo , Células Cultivadas , AMP Cíclico/metabolismo , Relação Dose-Resposta a Droga , Humanos , Hibridização in Situ Fluorescente , Osteocalcina/biossíntese , RNA Mensageiro/metabolismo , Receptores de Prostaglandina/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Fatores de Tempo
14.
J Periodontol ; 75(9): 1227-32, 2004 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-15515338

RESUMO

BACKGROUND: The role of nitric oxide (NO) on bone metabolism is controversial, since it can either stimulate bone formation or resorption. We investigated the effect of local administration of the NO donor isosorbide in an experimental periodontal disease model. METHODS: Wistar rats were subjected to a ligature placement around the cervix of the right second upper molar and were sacrificed after 11 days. Alveolar bone loss was measured in one quadrant as the sum of the distances between the cuspid tip and the alveolar bone along the axis of each molar root, which was subtracted from the contralateral side, used as unligated control. The semiquantitative histopathological scale of the periodontium was based on cell infiltration and alveolar bone and cementum integrity. Groups were treated with a gel containing 1% or 5% isosorbide applied to the vestibular side of the molar gingiva 1 hour before the placement of the ligature and then twice daily until sacrifice. Controls included one group subjected to periodontitis and no treatment (NT) and another that received the gel containing just the vehicle (V). RESULTS: The application of the vehicle gel produced an increase of the alveolar bone resorption, without altering the inflammatory changes, compared to the NT group. The 5% isosorbide produced a significant reduction of the alveolar bone resorption, compared to V and NT. This reduction was confirmed by histological analysis, showing less inflammatory cell infiltration and preservation of the cementum and the alveolar process. CONCLUSION: Local application of isosorbide reduces alveolar bone resorption in experimental periodontal disease in rats, suggesting a local anti-inflammatory effect of isosorbide.


Assuntos
Perda do Osso Alveolar/prevenção & controle , Isossorbida/uso terapêutico , Doadores de Óxido Nítrico/uso terapêutico , Periodontite/prevenção & controle , Perda do Osso Alveolar/patologia , Processo Alveolar/efeitos dos fármacos , Processo Alveolar/patologia , Animais , Cemento Dentário/efeitos dos fármacos , Cemento Dentário/patologia , Dentina/efeitos dos fármacos , Dentina/patologia , Modelos Animais de Doenças , Gengiva/efeitos dos fármacos , Gengiva/patologia , Dente Molar/patologia , Ligamento Periodontal/efeitos dos fármacos , Ligamento Periodontal/patologia , Veículos Farmacêuticos , Ratos , Ratos Wistar
15.
J Periodontol ; 71(6): 1009-14, 2000 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10914805

RESUMO

BACKGROUND: Prostaglandins are implicated in periodontal bone destruction. We investigated the effect of a non-selective cyclooxygenase (COX) inhibitor (indomethacin-IND) or a type 2 COX inhibitor (meloxicam-MLX) in an experimental periodontal disease (EPD) model. METHODS: Wistar rats were subjected to placement of a nylon thread ligature around the maxillary molars and sacrificed after 7 days. Alveolar bone loss (ABL) was measured in one quadrant as the distance between the cemento-enamel junction and the alveolar bone. The other quadrant was processed for histopathologic analysis. Daily weight and white blood cell count were recorded. Groups were treated subcutaneously for 7 days with either IND (0.5, 1, or 2 mg/kg) or MLX (0.75, 1.5, or 3 mg/kg). Controls received no treatment. Macroscopic analysis of the gastric mucosa was done. The control group did not receive any manipulation, and a non-treated group consisted of rats subjected to periodontitis that received no pharmacological treatment. RESULTS: In the non-treated (NT) group, there was significant ABL, severe mononuclear influx, and an increase in osteoclast numbers. Significant neutrophilia and lymphomonocytosis occurred at 6 hours and at 7 days, respectively, as compared to controls. Significant weight loss persisted until the seventh day in the NT group. Both IND and MLX reduced ABL and histopathologic changes. Neutrophilia and lymphomonocytosis were also significantly reversed. Both IND and MLX induced earlier weight recovery. The stomachs of the IND (1 and 2 mg/kg) groups presented hemorrhage and ulcers, whereas in the MLX-treated groups, there were mild petechiae just in the 3 mg/kg group. CONCLUSIONS: COX inhibition prevented ABL in this experimental periodontal disease model. MLX displays similar efficacy and less gastric damage than IND. MLX may provide a better risk/benefit ratio in the treatment of human periodontitis than non-selective COX inhibitors.


Assuntos
Perda do Osso Alveolar/prevenção & controle , Inibidores de Ciclo-Oxigenase/uso terapêutico , Isoenzimas/antagonistas & inibidores , Periodontite/prevenção & controle , Peroxidases/antagonistas & inibidores , Processo Alveolar/patologia , Animais , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/efeitos adversos , Anti-Inflamatórios não Esteroides/uso terapêutico , Peso Corporal , Contagem de Células , Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase/administração & dosagem , Inibidores de Ciclo-Oxigenase/efeitos adversos , Modelos Animais de Doenças , Indometacina/administração & dosagem , Indometacina/efeitos adversos , Indometacina/uso terapêutico , Injeções Subcutâneas , Contagem de Leucócitos , Leucócitos Mononucleares/efeitos dos fármacos , Leucócitos Mononucleares/patologia , Leucocitose/patologia , Leucocitose/prevenção & controle , Masculino , Meloxicam , Dente Molar , Neutrófilos/efeitos dos fármacos , Neutrófilos/patologia , Osteoclastos/patologia , Prostaglandina-Endoperóxido Sintases , Ratos , Ratos Wistar , Estômago/efeitos dos fármacos , Tiazinas/administração & dosagem , Tiazinas/efeitos adversos , Tiazinas/uso terapêutico , Tiazóis/administração & dosagem , Tiazóis/efeitos adversos , Tiazóis/uso terapêutico , Colo do Dente/patologia
16.
Braz J Med Biol Res ; 35(5): 613-6, 2002 May.
Artigo em Inglês | MEDLINE | ID: mdl-12011948

RESUMO

Matrix metalloproteinases (MMP) are considered to be key initiators of collagen degradation, thus contributing to bone resorption in inflammatory diseases. We determined whether subantimicrobial doses of doxycycline (DX) (< or =10 mg kg-1 day-1), a known MMP inhibitor, could inhibit bone resorption in an experimental periodontitis model. Thirty male Wistar rats (180-200 g) were subjected to placement of a nylon thread ligature around the maxillary molars and sacrificed after 7 days. Alveolar bone loss (ABL) was measured macroscopically in one hemiarcade and the contralateral hemiarcade was processed for histopathologic analysis. Groups of six animals each were treated with DX (2.5, 5 or 10 mg kg-1 day-1, sc, 7 days) and compared to nontreated (NT) rats. NT rats displayed significant ABL, severe mononuclear cell influx and increase in osteoclast numbers, which were significantly reduced by 5 or 10 mg kg-1 day-1 DX. These data show that DX inhibits inflammatory bone resorption in a manner that is independent of its antimicrobial properties.


Assuntos
Perda do Osso Alveolar/prevenção & controle , Antibacterianos/uso terapêutico , Doxiciclina/uso terapêutico , Periodontite/tratamento farmacológico , Animais , Antibacterianos/administração & dosagem , Doxiciclina/administração & dosagem , Arcada Osseodentária , Masculino , Inibidores de Metaloproteinases de Matriz , Periodontite/fisiopatologia , Ratos , Ratos Wistar
17.
Braz J Med Biol Res ; 46(10): 839-43, 2013 10.
Artigo em Inglês | MEDLINE | ID: mdl-24141611

RESUMO

Paracoccidioidomycosis (PCM) is a chronic systemic mycosis caused by the inhalation of the thermally dimorphic fungus Paracoccidioides brasiliensis as well as the recently described P. lutzii. Because the primary infection occurs in the lungs, we investigated the differential involvement of the right and left lungs in experimental P. brasiliensis infection. Lungs were collected from C57BL/6 mice at 70 days after intravenous infection with 1×106 yeast cells of a virulent strain of P. brasiliensis (Pb18). The left lung, which in mice is smaller and has fewer lobes than the right lung, yielded increased fungal recovery associated with a predominant interleukin-4 response and diminished synthesis of interferon-γ and nitric oxide compared with the right lung. Our data indicate differential involvement of the right and left lungs during experimental PCM. This knowledge emphasizes the need for an accurate, standardized protocol for tissue collection during studies of experimental P. brasiliensis infection, since experiments using the same lungs favor the collection of comparable data among different mice.


Assuntos
Pneumopatias Fúngicas/microbiologia , Pulmão/microbiologia , Paracoccidioides , Paracoccidioidomicose/microbiologia , Animais , Modelos Animais de Doenças , Interferon gama/análise , Interleucina-10/análise , Interleucina-4/análise , Masculino , Camundongos Endogâmicos C57BL , Óxido Nítrico/análise , Fatores de Tempo
18.
Br J Pharmacol ; 164(2b): 828-35, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21557731

RESUMO

BACKGROUND AND PURPOSE: We investigated the effect of the phosphodiesterase-5 inhibitor, tadalafil, on the acute hypernociception in rat models of arthritis. EXPERIMENTAL APPROACH: Rats were treated with either an intra-articular injection of zymosan (1 mg) or surgical transection of the anterior cruciate ligament (as an osteoarthritis model). Controls received saline intra-articular or sham operation respectively. Joint pain was evaluated using the articular incapacitation test measured over 6 h following zymosan or between 4 and 7 days after anterior cruciate ligament transection. Cell counts, tumour necrosis factor-α (TNF-α), interleukin-1 (IL-1), and the chemokine, cytokine-induced neutrophil chemoattractant-1 (CINC-1) were measured in joint exudates 6 h after zymosan. Groups received tadalafil (0.02-0.5 mg·kg⁻¹ per os) or saline 2 h after intra-articular zymosan. Other groups received the µ-opioid receptor antagonist naloxone or the cGMP inhibitor 1H-[1,2,4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ) before tadalafil. KEY RESULTS: Tadalafil dose-dependently inhibited hypernociception in zymosan and osteoarthritis models. In zymosan-induced arthritis, tadalafil significantly decreased cell influx and TNF-α release but did not alter IL-1 or CINC-1 levels. Pretreatment with ODQ but not with naloxone prevented the anti-inflammatory effects of tadalafil. CONCLUSIONS AND IMPLICATIONS: Therapeutic oral administration of tadalafil provided analgesia mediated by guanylyl cyclase and was independent of the release of endogenous opioids. This effect of tadalafil was associated with a decrease in neutrophil influx and TNF-α release in inflamed joints.


Assuntos
Artrite Experimental/tratamento farmacológico , Artrite Experimental/metabolismo , Carbolinas/farmacologia , Nociceptividade/efeitos dos fármacos , Fator de Necrose Tumoral alfa/metabolismo , Analgésicos/farmacologia , Animais , Anti-Inflamatórios/farmacologia , Artralgia/tratamento farmacológico , Artralgia/metabolismo , Artrite Experimental/induzido quimicamente , Quimiocina CXCL1/metabolismo , Quimiocinas/metabolismo , GMP Cíclico/antagonistas & inibidores , Guanilato Ciclase/metabolismo , Injeções Intra-Articulares , Interleucina-1/metabolismo , Articulações/efeitos dos fármacos , Articulações/metabolismo , Masculino , Naloxona/farmacologia , Antagonistas de Entorpecentes/farmacologia , Neutrófilos/efeitos dos fármacos , Neutrófilos/metabolismo , Osteoartrite/tratamento farmacológico , Osteoartrite/metabolismo , Oxidiazóis/farmacologia , Quinoxalinas/farmacologia , Ratos , Ratos Wistar , Tadalafila , Zimosan/farmacologia
19.
Acta Trop ; 119(2-3): 203-5, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21651884

RESUMO

Histoplasmosis is a systemic infection caused by the fungus Histoplasma capsulatum. Environmental sources of infection for humans and animals in certain regions and the prevalence of infection in animals are frequently unknown. Because of the clinical and epidemiological similarities between histoplasmosis and leishmaniasis in northeastern Brazil, we decided to investigate the serologic evidence of H. capsulatum in dogs, considering that these animals can act as sentinels for histoplasmosis. A total of 224 serum samples from dogs were tested for antibodies against H. capsulatum through immunodiffusion. A total of 128 (57.14%) samples were positive for leishmaniasis by indirect immunofluorescence assay and four (1.78%) samples were positive for antibodies against H. capsulatum. Immunological evidence of the co-existence of histoplasmosis and leishmaniasis in dogs living in urban areas was observed. Diagnosis and clinical management of these diseases in endemic areas should be improved by veterinarians.


Assuntos
Anticorpos Antifúngicos/sangue , Doenças do Cão/epidemiologia , Doenças do Cão/microbiologia , Histoplasma/imunologia , Histoplasmose/veterinária , Leishmaniose/veterinária , Animais , Anticorpos Antiprotozoários/sangue , Brasil/epidemiologia , Comorbidade , Cães , Feminino , Histoplasmose/epidemiologia , Leishmaniose/complicações , Leishmaniose/epidemiologia , Masculino , Testes Sorológicos
20.
Acta Reumatol Port ; 35(1): 82-4, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20518148

RESUMO

Tenosynovitis caused by tuberculosis (TB) is a rare presentation of this disease usually reported in immunocompromised patients. We describe a patient diagnosed with TB tenosynovitis of the left upper limb with no history of immunodeficiency. Although appearing in an endemic area the time to diagnosis was 6 years due to the absence of acid-fast stained bacilli in the first cultures despite histopathology showing a granulomatous lesion. Institution of pharmacological treatment and surgical debridément led to improvement within one month. The authors emphasize the need for early intervention in order to halt disease progression and avoid sequelae.


Assuntos
Síndrome do Túnel Carpal/microbiologia , Tenossinovite/microbiologia , Tuberculose/complicações , Feminino , Humanos , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA